CN102414196A - 改进的方法 - Google Patents

改进的方法 Download PDF

Info

Publication number
CN102414196A
CN102414196A CN2010800195527A CN201080019552A CN102414196A CN 102414196 A CN102414196 A CN 102414196A CN 2010800195527 A CN2010800195527 A CN 2010800195527A CN 201080019552 A CN201080019552 A CN 201080019552A CN 102414196 A CN102414196 A CN 102414196A
Authority
CN
China
Prior art keywords
revlimid
lenalidomide
nitro
alcohol
described method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800195527A
Other languages
English (en)
Chinese (zh)
Inventor
维纳亚克·戈文德·戈雷
维纳伊·库玛·舒克拉
希尔雅斯·布安达里
苏雷什·哈斯贝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generics UK Ltd
Original Assignee
Generics UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics UK Ltd filed Critical Generics UK Ltd
Publication of CN102414196A publication Critical patent/CN102414196A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Optical Communication System (AREA)
  • Lighting Device Outwards From Vehicle And Optical Signal (AREA)
  • Glass Compositions (AREA)
CN2010800195527A 2009-03-02 2010-03-01 改进的方法 Pending CN102414196A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN383/KOL/2009 2009-03-02
IN383KO2009 2009-03-02
IN463KO2009 2009-03-16
IN463/KOL/2009 2009-03-16
PCT/GB2010/050352 WO2010100476A2 (en) 2009-03-02 2010-03-01 Improved process

Publications (1)

Publication Number Publication Date
CN102414196A true CN102414196A (zh) 2012-04-11

Family

ID=54290149

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800195527A Pending CN102414196A (zh) 2009-03-02 2010-03-01 改进的方法

Country Status (16)

Country Link
US (1) US8946265B2 (https=)
EP (1) EP2403845B1 (https=)
JP (1) JP5727944B2 (https=)
CN (1) CN102414196A (https=)
AU (1) AU2010220204B2 (https=)
CA (1) CA2753241C (https=)
CY (1) CY1115376T1 (https=)
DK (1) DK2403845T3 (https=)
ES (1) ES2487215T3 (https=)
HR (1) HRP20140686T1 (https=)
NZ (1) NZ595492A (https=)
PL (1) PL2403845T3 (https=)
PT (1) PT2403845E (https=)
SI (1) SI2403845T1 (https=)
SM (1) SMT201400100B (https=)
WO (1) WO2010100476A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102838586A (zh) * 2012-09-20 2012-12-26 重庆泰濠制药有限公司 一种制备来那度胺的方法
CN103601717A (zh) * 2013-10-09 2014-02-26 湖南华腾制药有限公司 一种来那度胺的新型制备方法

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
TWI475014B (zh) * 2009-09-17 2015-03-01 Scinopharm Taiwan Ltd 固體形態的３－（４－胺基－１－側氧基－１，３－二氫－異吲哚－２－基）－哌啶－２，６－二酮及其製造方法
WO2011064574A1 (en) 2009-11-24 2011-06-03 Generics [Uk] Limited Hplc method for detecting lenalidomide
WO2011111053A1 (en) * 2010-03-08 2011-09-15 Natco Pharma Limited Anhydrous lenalidomide form-i
KR20130050952A (ko) 2010-06-16 2013-05-16 브루스 챈들러 메이 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
WO2013005229A1 (en) * 2011-07-05 2013-01-10 Hetero Research Foundation Process for lenalidomide
US9540341B2 (en) 2011-07-19 2017-01-10 Amplio Pharma, Llc Crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
WO2014164285A2 (en) 2013-03-13 2014-10-09 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of vasculitis
RU2015134423A (ru) 2013-03-13 2017-04-26 Инфламматори Респонс Ресёрч, Инк. Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств
MX382776B (es) 2013-03-13 2025-03-13 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
US9808450B2 (en) 2013-03-26 2017-11-07 Celgene Corporation Solid forms comprising 3-(4-amino-1-OXO-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof
LV14985B (lv) 2013-10-14 2015-06-20 Latvijas Organiskās Sintēzes Institūts Lenalidomīda iegūšanas process
WO2014155371A2 (en) * 2014-04-26 2014-10-02 Shilpa Medicare Limited Crystalline lenalidomide process
WO2016024286A2 (en) * 2014-08-11 2016-02-18 Avra Laboratories Pvt. Ltd. An improved process for synthesis of lenalidomide
EP3183244B1 (en) * 2014-08-19 2019-04-10 Synthon BV Process for making crystalline form a of lenalidomide
WO2016044095A1 (en) 2014-09-15 2016-03-24 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
WO2017109041A1 (en) * 2015-12-22 2017-06-29 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
US10899793B2 (en) 2016-05-27 2021-01-26 Regents Of The University Of Minnesota Melanocortin ligands and methods of use thereof
US11124541B2 (en) 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
EP3687987A4 (en) * 2017-09-27 2021-03-24 Biocon Limited CRYSTALLINE FORMS OF LENALIDOMIDE
US11452722B2 (en) 2018-01-11 2022-09-27 Natco Pharma Limited Stable pharmaceutical compositions comprising lenalidomide
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof
CN111196800B (zh) * 2018-11-19 2022-10-11 欣凯医药化工中间体（上海）有限公司 一种制备来那度胺的方法
WO2021236518A1 (en) 2020-05-19 2021-11-25 IRR, Inc. Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof
WO2022144924A1 (en) * 2021-01-04 2022-07-07 Avra Laboratories Pvt. Ltd. An improved process for synthesis of lenalidomide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
BRPI0514865A (pt) * 2004-09-03 2008-06-24 Celgene Corp processo para preparar um composto
US8304250B2 (en) 2007-04-16 2012-11-06 Momenta Pharmaceuticals, Inc. Multi-dimensional chromatographic methods for separating N-glycans
CA2709262A1 (en) 2007-12-14 2009-06-25 Generics [Uk] Limited New hplc method
CA2717326C (en) 2008-03-11 2018-10-23 Dr. Reddy's Laboratories Ltd. Preparation of lenalidomide
WO2010061209A1 (en) 2008-11-03 2010-06-03 Generics [Uk] Limited A crystalline form of lenalidomide and a process for its preparation
WO2011064574A1 (en) 2009-11-24 2011-06-03 Generics [Uk] Limited Hplc method for detecting lenalidomide

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102838586A (zh) * 2012-09-20 2012-12-26 重庆泰濠制药有限公司 一种制备来那度胺的方法
CN103601717A (zh) * 2013-10-09 2014-02-26 湖南华腾制药有限公司 一种来那度胺的新型制备方法

Also Published As

Publication number Publication date
CA2753241C (en) 2015-06-16
AU2010220204B2 (en) 2015-10-08
SI2403845T1 (sl) 2014-09-30
DK2403845T3 (da) 2014-08-04
PL2403845T3 (pl) 2014-09-30
US8946265B2 (en) 2015-02-03
CY1115376T1 (el) 2017-01-04
ES2487215T3 (es) 2014-08-20
WO2010100476A2 (en) 2010-09-10
PT2403845E (pt) 2014-08-04
SMT201400100B (it) 2014-11-10
NZ595492A (en) 2013-07-26
JP5727944B2 (ja) 2015-06-03
US20120071509A1 (en) 2012-03-22
JP2012519207A (ja) 2012-08-23
EP2403845A2 (en) 2012-01-11
HRP20140686T1 (hr) 2014-09-26
WO2010100476A3 (en) 2011-06-16
AU2010220204A1 (en) 2011-10-20
EP2403845B1 (en) 2014-04-30
CA2753241A1 (en) 2010-09-10

Similar Documents

Publication Publication Date Title
CN102414196A (zh) 改进的方法
TWI545124B (zh) ６，７－不飽合－７－胺甲醯基嗎啡喃衍生物之結晶及其製造方法
JP2006249105A (ja) ゾルピデムヘミタートレイト
KR102142797B1 (ko) 피리디닐아미노피리미딘 유도체의 메실레이트 염의 결정질 형태, 그의 제조 방법, 및 그의 용도
JP2019523273A (ja) ベリノスタットの多形形態、およびその調製のためのプロセス
US20150094473A1 (en) Solid forms of 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
EP3042893B1 (en) Novel crystalline arylalkylamine compound and method for producing same
CN101044142A (zh) 嘌呤衍生物
JP7763848B2 (ja) Ｋｉｔ－およびｐｄｇｆｒａ－媒介性疾患を治療するための化合物を製造するための合成方法および中間生成物
US8598201B2 (en) Polymorphs of 6-(piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride
KR20220137084A (ko) 아미드 화합물, 및 이들의 결정질 및 염 형태의 제조 방법
JP7736311B2 (ja) ピリミジノジアゼピン誘導体の結晶性形態
CA2843773C (en) Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
TWI869199B (zh) 4-甲氧基吡咯衍生物的製造方法
US20240327374A1 (en) Lenalidomide process
JP2012503641A (ja) アカンプロセートカルシウムの多形体
CN121293164A (zh) 一种小分子化合物及其制备方法与在抗癌药物中的应用
WO2026082074A1 (zh) Parg抑制剂的盐型、晶型及其组合物、制备方法和应用
US20050192298A1 (en) Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
BR112020003557A2 (pt) composto de triaminopirimidina, forma cristalina, processo para a preparação do composto e composição
NZ620864B2 (en) Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
HK1223928B (en) Novel crystalline arylalkylamine compound and method for producing same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB03 Change of inventor or designer information

Inventor after: Gore Vinayak Govind

Inventor after: Shukla Vinaykumar

Inventor after: Syllas Sykent Bouandari

Inventor after: Hasbe Suresh

Inventor before: Gore Vinayak Govind

Inventor before: Shukla Vinaykumar

Inventor before: Bhandari Sheryas

Inventor before: Hasbe Suresh

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: GORE VINAYAK GOVIND SHUKLA VINAY KNMAR BHANDARI SHERYAS HASBE SURESH TO: GORE VINAYAK GOVIND SHUKLA VINAY KNMAR BHANDARI SHERYAS SHRIKANT HASBE SURESH

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120411